Aug 8, 2024 4:30 pm EDT SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 23, 2024 7:00 am EDT SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
May 8, 2024 4:30 pm EDT SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 30, 2024 4:05 pm EDT SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
Apr 9, 2024 4:05 pm EDT SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Mar 28, 2024 4:01 pm EDT SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
Jan 29, 2024 5:15 pm EST SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
Jan 5, 2024 8:30 am EST SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
Nov 13, 2023 5:17 pm EST SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update